references

Cannabinoids & Cancer

  1. McAllister, S. D., et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6, (2007).
  2. Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics 318, (2006).
  3. Leyva-Illades, D. & DeMorrow, S. Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. Cancer Management and Research vol. 5 Preprint at https://doi.org/10.2147/CMAR.S35175 (2013).
  4. Ryberg, E. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152, (2007).
  5. Whyte, L. S. et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106, (2009).
  6. Zhou, X. L., et al. The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling. Acta Pharmacol Sin 39, (2018).
  7. Takeda, S. et al. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol Lett 214, (2012).
  8. Takeda, S. et al. Down-regulation of cyclooxygenase-2 (cox-2) by cannabidiolic acid in human breast cancer cells. Journal of Toxicological Sciences 39, (2014).
  9. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163, (2011).
  10. Anavi-Goffer, S. et al. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. Journal of Biological Chemistry 287, (2012).
  11. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9, (2010).
  12. Blasco-Benito, S. et al. Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer. Proc Natl Acad Sci U S A 116, (2019).
  13. Takeda, S. et al. Δ9-tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor
    β (ERβ). Chem Res Toxicol 26, (2013).
  14. Bardon, S., et al. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 32, (1998).
  15. Miller, J. A. et al. Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer. Cancer Prevention Research 6, (2013).
  16. Miller, J. A., et al. D-Limonene: A bioactive food component from citrus and evidence for a potential role in breast cancer prevention and treatment. Oncology Reviews vol. 5 Preprint at https://doi.org/10.1007/s12156- 010-0066-8 (2011).
  17. Laezza, C. et al. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer 48, (2012).
  18. Caffarel, M. M., et al. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66, (2006).
  19. Laezza, C., et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 580, (2006).
  20. Ford, L. A. et al. A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160, (2010).
  21. Stewart, J. M. TRPV6 as a target for cancer therapy. Journal of Cancer vol. 11 Preprint at https://doi.org/10.7150/jca.31640 (2020).
  22. Bolanz, K. A., et al. The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther 7, (2008).
  23. Liu, J. et al. TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3β pathway. Tumor Biology 35, (2014).
  24. Nomura, D. K. et al. Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis. Cell 140, (2010).
  25. Kargl, J. et al. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br J Pharmacol 173, (2016).
  26. Aviello, G. et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med 90, (2012).
  27. Romano, B. et al. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine 21, (2014).
  28. Borrelli, F. et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis 35, (2014).
  29. Pagano, E. et al. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. Pharmacol Res 119, (2017).
  30. Cianchi, F. et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide de novo synthesis in colon cancer cells. Clinical Cancer Research 14, (2008).
  31. Yongsong Liu, et al. The Role of Cyclooxygenase-2 in Colorectal Carcinogenesis. Clin Colorectal Cancer Sep;16(3), 165–172 (2017).
  32. Arbabian, A. et al. Mutations in calmodulin-binding domains of TRPV4/6 channels confer invasive properties to colon adenocarcinoma cells. Channels 14, (2020).
  33. Liu, X. et al. Activation of PTEN by inhibition of TRPV4 suppresses colon cancer development. Cell Death Dis 10, (2019).
  34. Ferro, R. et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 37, (2018).
  35. Carracedo, A. et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress- related genes. Cancer Res 66, (2006).
  36. Dando, I. et al. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis 4, (2013).
  37. Donadelli, M. et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2, (2011).
  38. Andradas, C. et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK.
    Oncogene 30, (2011).
  39. Song, H. et al. Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer. Oncol Rep 39, (2018).
  40. Liu, Z. et al. TRPM8: a potential target for cancer treatment. Journal of Cancer Research and Clinical Oncology
    vol. 142 Preprint at https://doi.org/10.1007/s00432-015-2112-1 (2016).
  41. Polvani, S., et al. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology vol. 22 Preprint at https://doi.org/10.3748/wjg.v22.i8.2441 (2016).
  42. Sun WH, et al. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275, 247–255 (2009).
  43. Ramer, R. et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-
  44. The FASEB Journal 26, (2012).
  45. Milian, L. et al. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS One 15, (2020).
  46. Ramer, R. et al. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 12, (2013).
  47. Munson, A. E., et al. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55, (1975).
  48. Preet A, et al. Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene Jan 10;27(3), 339–346 (2008).
  49. Staiano, R. I. et al. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol 99, (2016).
  50. Ravi, J., et al. & Ganju, R. K. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Mol Carcinog 55, (2016).
  51. Wick, M. et al. Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 62, (2002).
  52. Geraci, M. W. TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129, (2018).
  53. To, K. K. W., Wu, W. K. K. & Loong, H. H. F. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. Eur J Pharmacol 823, (2018).
  54. Reddy, A. T., et al. PPAR γ as a Novel Therapeutic Target in Lung Cancer. PPAR Research vol. 2016 Preprint at https://doi.org/10.1155/2016/8972570 (2016).
  55. Winkler, K. et al. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells. Oncotarget 7, (2016).
  56. Liu, R., et al. Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed. European Journal of Pharmacology vol. 769 Preprint at https://doi.org/10.1016/j.ejphar.2015.11.007 (2015).
  57. Leyva-Illades, D. & DeMorrow, S. Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. Cancer Management and Research vol. 5 Preprint at https://doi.org/10.2147/CMAR.S35175 (2013).
  58. De Petrocellis, L. et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro- apoptotic effects and underlying mechanisms. Br J Pharmacol 168, (2013).
  59. Ruiz L, et al. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor- independent mechanism. FEBS Lett. Sep 24;458(3), 400–404 (1999).
  60. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, (2000).
  61. Nithipatikom, K. et al. Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. Endocrinology 153, (2012).
  62. Sarfaraz, S., et al. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G 1 cell cycle arrest. Journal of Biological Chemistry 281, (2006).
  63. Olea-Herrero, N., et al. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R()- Methanandamide and JWH-015: Involvement of CB 2. Br J Cancer 101, (2009).
  64. Pĩeiro, R., et al. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, (2011).
  65. Wissenbach, U. et al. TRPV6 and prostate cancer: Cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression. Biochem Biophys Res Commun 322, (2004).
  66. Kirschenbaum, A., et al. The role of cyclooxygenase-2 in prostate cancer. in Urology vol. 58 (2001).
  67. de Petrocellis, L. et al. Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica vol. 204 Preprint at https://doi.org/10.1111/j.1748-1716.2011.02338.x (2012).
  68. Ghovanloo, M. R. et al. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. Journal of Biological Chemistry 293, (2019).
  69. Ross HR, et al. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem Jun 6;283(23), 16124–34 (2008).
  70. Hill, A. J. et al. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci Lett 566, (2014).
  71. Abraham, A. D. et al. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. Neuropsychopharmacology 45, (2020).
  72. Xiong, W. et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
    Journal of Experimental Medicine 209, (2012).
  73. Ahrens, J. et al. The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology 83, (2009).
  74. Costa, B., et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556, (2007).
  75. Costa, B. et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369, (2004).
  76. King, K. M. et al. Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 174, (2017).
  77. Philpott, H. T., et al. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain 158, (2017).
  78. Maione, S. et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162, (2011).
  79. Toth, C. C., et al. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain 6, (2010).
  80. Rock, E. M., et al. Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. Psychopharmacology (Berl) 235, (2018).
  81. Russo EB, H. AG. Role of cannabinoids in pain management. in In Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches: The AMERICAN ACADEMY OF PAIN MEDICINE Textbook on Patient Management 181–197 (New York, NY: Springer New York, 2012).
  82. Abrams, D. I. et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 68, (2007).
  83. R.J., E. et al. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial.
    Neuropsychopharmacology vol. 34 Preprint at (2009).
  84. Ware, M. A. et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ. Canadian Medical Association Journal 182, (2010).
  85. Zajicek, J. P. et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76, (2005).
  86. Weizman, L. et al. Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity.
    Neurology 91, (2018).
  87. Xiong, W. et al. Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. Nat Chem Biol 7, (2011).
  88. Wise, L. E., et al. Evaluation of fatty acid amides in the carrageenan-induced paw edema model.
    Neuropharmacology 54, (2008).
  89. R.G., P. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9- tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology vol. 153 Preprint at (2008).
  90. Rosenthaler, S. et al. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicol Teratol 46, (2014).
  91. Rock, E. M. & Parker, L. A. Synergy Between Cannabidiol, Cannabidiolic Acid, and Δ9-Tetrahydrocannabinol in the Regulation of Emesis in the Suncus Murinus (House Musk Shrew). Behavioral Neuroscience 129, (2015).
  92. Bolognini, D. et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168, (2013).
  93. Rock EM, P. LA. Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. Front Pharmacol. Jul 26;7:221, (2016).
  94. Darmani, N. A. Δ9-Tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, (2001).
  95. Darmani, N. A. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 69, (2001).
  96. Darmani, N. A. Mechanisms of broad-spectrum antiemetic efficacy of cannabinoids against chemotherapy- induced acute and delayed vomiting. Pharmaceuticals vol. 3 Preprint at https://doi.org/10.3390/ph3092930 (2010).
  97. Ray, A. P., Griggs, L. & Darmani, N. A. Δ9-Tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behavioural Brain Research 196, (2009).
  98. Wang, Y., et al. The antiemetic interaction of Δ9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav 91, (2009).
  99. Kwiatkowska, M., et al. comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 174, (2004).
  100. Van Sickle, M. D., et al. Δ9-tetrahydrocannabinol selectively acts on CB 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285, (2003).
  101. Parker, L. A. & Mechoulam, R. Cannabinoid Agonists and Antagonists Modulate Lithium-induced Conditioned Gaping in Rats. Integrative Physiological and Behavioral Science 38, (2003).
  102. Limebeer, C. L., Hall, G. & Parker, L. A. Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea. Physiol Behav 88, (2006).
  103. Rock, E. M. et al. Interaction between non-psychotropic cannabinoids in marihuana: Effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) 215, (2011).
  104. Rock, E. M., et al. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9- tetrahydrocannabivarin (THCV), to produce CB 1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol 170, (2013).
  105. Rock, E. M., et al. Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 170, (2013).
  106. Chow, R. et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care in Cancer vol. 28 Preprint at https://doi.org/10.1007/s00520-019-05280-4 (2020).
  107. Parker, L. A., Kwiatkowska, M., Burton, P. & Mechoulam, R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 171, (2004).
  108. Rock EM, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol Apr;165(8), 2620–34 (2012).